Model identifies ideal vancomycin concentrations for infants

Study researcher Amanda Gwee, PhD, a general pediatrician, infectious disease physician and clinical pharmacologist from the Royal Children's Hospital Melbourne, Australia, told Infectious Diseases in Children that the current approach to vancomycin treatment in infants is to measure the lowest...

Full description

Saved in:
Bibliographic Details
Published inInfectious diseases in children Vol. 32; no. 8; p. 10
Main Author Bortz, Katherine
Format Journal Article
LanguageEnglish
Published Thorofare SLACK INCORPORATED 01.08.2019
Subjects
Antibiotics
Children & youth
Drug dosages
Hospitals
Infectious diseases
Patients
Pediatrics
Researchers
Staphylococcus infections
Studies
Melbourne Victoria Australia
Online AccessGet full text

Cover

More Information
Summary:Study researcher Amanda Gwee, PhD, a general pediatrician, infectious disease physician and clinical pharmacologist from the Royal Children's Hospital Melbourne, Australia, told Infectious Diseases in Children that the current approach to vancomycin treatment in infants is to measure the lowest level of the antibiotic in the blood, or the trough level. [...]we have now identified new values for vancomycin trough levels that clinicians can target to ensure that all babies receive doses of vancomycin that will be effective to treat S. aureus infections" - by Katherine Bortz ? PERSPECTIVE In critically ill infants and children, vancomycin remains the mainstay of our therapy against MRSA and other gram-positive pathogens. Both efficacy and toxicity are a function of the overall vancomycin concentration over time, which is measured as the AUC. Because the AUC cannot be directly measured, it is the standard of care to monitor a patient's trough vancomycin concentration and then extrapolate from the trough to the AUC level.
ISSN:1044-9779